Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1440-1456
Open Access | Times Cited: 13

Showing 13 citing articles:

Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning
Gabriella O. Estevam, Edmond M. Linossi, J. N. K. Rao, et al.
(2025)
Open Access
Resistance to Allosteric Inhibitors
Ian R Outhwaite, Isabelle Kwan, Neil P. Shah, et al.
(2025)
Closed Access
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning
Gabriella O. Estevam, Edmond M. Linossi, J. N. K. Rao, et al.
eLife (2025) Vol. 13
Open Access
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer
Martin Sattler, Ravi Salgia
Cell Reports Medicine (2025), pp. 101983-101983
Open Access
Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor Binding
Sukrit Singh, Vytautas Gapsys, Matteo Aldeghi, et al.
The Journal of Physical Chemistry B (2025)
Open Access
Resistance to Allosteric Inhibitors
Ian R Outhwaite, Isabelle Kwan, Ariel Leyte-Vidal, et al.
Journal of Molecular Biology (2025), pp. 169133-169133
Closed Access
Precision Oncology: 2024 in Review
Matteo Repetto, Nicole Fernandez, Alexander Drilon, et al.
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2332-2345
Closed Access | Times Cited: 2
Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma
Victor R. Vaz, Malini Gandhi, Biagio Ricciuti, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology
Jennifer A. Marks, Nishant Gandhi, Balázs Halmos, et al.
Lung Cancer (2024) Vol. 196, pp. 107935-107935
Closed Access | Times Cited: 1
Prospective evaluation of structure-based simulations reveal their ability to predict the impact of kinase mutations on inhibitor binding
Sukrit Singh, Vytautas Gapsys, Matteo Aldeghi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients
Solange Rivas, Romina V. Sepúlveda, Ignacio E. Tapia, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13715-13715
Open Access | Times Cited: 1
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning
Gabriella O. Estevam, Edmond M. Linossi, J. N. K. Rao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning
Gabriella O. Estevam, Edmond M. Linossi, J. N. K. Rao, et al.
eLife (2024) Vol. 13
Open Access
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning
Gabriella O. Estevam, Edmond M. Linossi, J. N. K. Rao, et al.
(2024)
Open Access
Page 1

Scroll to top